Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20405DOI Listing

Publication Analysis

Top Keywords

complete response
4
response patient
4
patient advanced
4
advanced melanoma
4
melanoma anti-pd-1
4
anti-pd-1 therapy
4
therapy associated
4
associated high
4
high frequency
4
frequency melanoma-infiltrating
4

Similar Publications

Objective: To explore the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) combined with a PD-1 antibody in improving complete clinical response (cCR) and organ preservation in patients with ultra-low rectal cancer.

Methods: This was a prospective phase II, single-arm, open-label trial. Patients with confirmed pMMR status T1-3aN0-1M0 retcal adenocarcinoma were included.

View Article and Find Full Text PDF

Miller Fisher syndrome (MFS) is a rare Guillain-Barré syndrome (GBS) variant. The global incidence of GBS is approximately one to two in 100,000 children (aged 0 to 15 years) per year. Miller Fisher syndrome represents a further small subset, with the incidence being one to two in 1,000,000 children.

View Article and Find Full Text PDF

Manganese (Mn)-sensing riboswitches protect bacteria from Mn toxicity by upregulating expression of Mn exporters. The Mn aptamers share key features but diverge in other important elements, including within the metal-binding core. Although X-ray crystal structures of isolated aptamers exist, these structural snapshots lack crucial details about how the aptamer communicates the presence or absence of ligand to the expression platform.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to determine the efficacy and safety of low-dose radiotherapy (LDR) for postoperative local chest wall recurrence of breast cancer.

Methods: The records of 52 patients with postoperative local chest wall recurrent breast cancer treated at our cancer center from January 2019 to December 2022. The t-test was used to compare the means of the LDR group and non LDR group.

View Article and Find Full Text PDF

Background: Transarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of the combination of these three treatments as a neoadjuvant modality in patients with locally advanced HCC.

Methods: The primary endpoint is overall survival (OS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!